218 related articles for article (PubMed ID: 34445387)
21. The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer.
Farfán N; Ocarez N; Castellón EA; Mejía N; de Herreros AG; Contreras HR
Sci Rep; 2018 Jul; 8(1):11467. PubMed ID: 30065348
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
23. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
24. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
25. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
26. Syndecan-1 facilitates breast cancer metastasis to the brain.
Sayyad MR; Puchalapalli M; Vergara NG; Wangensteen SM; Moore M; Mu L; Edwards C; Anderson A; Kall S; Sullivan M; Dozmorov M; Singh J; Idowu MO; Koblinski JE
Breast Cancer Res Treat; 2019 Nov; 178(1):35-49. PubMed ID: 31327090
[TBL] [Abstract][Full Text] [Related]
27. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
28. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
29. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
Brimo F; Vollmer RT; Friszt M; Corcos J; Bismar TA
BJU Int; 2010 Aug; 106(3):418-23. PubMed ID: 20002675
[TBL] [Abstract][Full Text] [Related]
30. The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle.
Hallberg G; Andersson E; Naessén T; Ordeberg GE
Reprod Biol Endocrinol; 2010 Apr; 8():35. PubMed ID: 20398359
[TBL] [Abstract][Full Text] [Related]
31. Expression and prognostic role of syndecan-2 in prostate cancer.
Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
[TBL] [Abstract][Full Text] [Related]
32. The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion.
Das SK; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Sarkar D; Emdad L; Fisher PB
Cancer Res; 2018 Jun; 78(11):2852-2863. PubMed ID: 29572229
[TBL] [Abstract][Full Text] [Related]
33. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
34. Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
Leighton X; Bera A; Eidelman O; Bubendorf L; Zellweger T; Banerjee J; Gelmann EP; Pollard HB; Srivastava M
PLoS One; 2018; 13(10):e0205837. PubMed ID: 30321230
[TBL] [Abstract][Full Text] [Related]
35. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Shimada K; Anai S; Fujii T; Tanaka N; Fujimoto K; Konishi N
J Pathol; 2013 Dec; 231(4):495-504. PubMed ID: 24549646
[TBL] [Abstract][Full Text] [Related]
36. Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains.
Zong F; Fthenou E; Castro J; Péterfia B; Kovalszky I; Szilák L; Tzanakakis G; Dobra K
Cell Prolif; 2010 Feb; 43(1):29-40. PubMed ID: 19840029
[TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase
Waldbillig F; Nitschke K; Abdelhadi A; von Hardenberg J; Nuhn P; Nientiedt M; Weis CA; Michel MS; Erben P; Worst TS
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575490
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 and KRAS Gene Expression Signature Associates With Patient Survival in Pancreatic Cancer.
Wu Y; Huang H; Fervers B; Lu L
Pancreas; 2020 Oct; 49(9):1187-1194. PubMed ID: 32898003
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of syndecan binding protein in colorectal carcinoma].
Liu H; Yang L; Ding Y; Zhao Z; Yu Q
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jul; 35(7):1003-7. PubMed ID: 26198950
[TBL] [Abstract][Full Text] [Related]
40. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
